Ajanta Pharma Promoter Aayush Agrawal Pledges 3.85 Lakh Shares for Loan Enhancement

Ajanta pharma promoter Aayush Agrawal has pledged 3,85,000 shares of the pharmaceutical company to enhance loan facilities. The pledge creation was disclosed to stock exchanges on March 31, 2026, in accordance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Details and Purpose

The pledge was created on March 30, 2026, by Aayush Agrawal in his capacity as trustee of Aayush Agrawal Trust. The stated reason for the pledge creation is to increase loan facilities. The pledged shares represent 0.31% of the company's total share capital.

Parameter:	Details
Pledged Shares:	3,85,000
Percentage of Total Capital:	0.31%
Date of Pledge Creation:	March 30, 2026
Purpose:	Increase loan facilities
Type of Encumbrance:	Pledge

Promoter Holdings and Encumbrance Status

Following this pledge creation, the encumbrance position of Aayush Agrawal Trust has been updated. The trust holds a total of 1,41,12,924 shares in Ajanta Pharma Limited, representing 11.30% of the total share capital.

Holding Details:	Current Position
Total Shares Held:	1,41,12,924
Percentage Holding:	11.30%
Previously Encumbered:	83,96,662 shares (6.72%)
New Encumbrance:	3,85,000 shares (0.31%)

Regulatory Compliance

The disclosure was made to both BSE and NSE on March 31, 2026, following the prescribed format under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company secretary of Ajanta Pharma Limited was also informed about the pledge creation as part of the regulatory compliance process.

Promoter Group Holdings Overview

The disclosure document reveals the comprehensive shareholding pattern of the promoter group. Other significant promoter holdings include Yogesh Agrawal Trust with 1,80,78,147 shares (14.47%) and Rajesh Agrawal Trust with 1,80,78,148 shares (14.47%). Gabs Investments Pvt Ltd holds 1,25,88,393 shares representing 10.08% of the total share capital.

The pledge creation is part of routine corporate financing activities and demonstrates the promoter's commitment to leveraging shareholding for business expansion and financial flexibility.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.85%	-3.91%	-6.75%	+15.39%	+5.72%	+138.25%

Ajanta Pharma Limited has officially confirmed to BSE and NSE that it does not qualify as a Large Corporate Entity under the SEBI regulatory framework for debt securities issuance. The confirmation was made in reference to SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which governs fund raising through debt securities by large entities.

Regulatory Compliance Disclosure

The pharmaceutical company submitted its formal disclosure on April 1, 2026, through Sr. VP – Legal & Company Secretary Gaurang Shah. The communication addressed both major stock exchanges where the company's shares are listed, ensuring comprehensive regulatory compliance.

Financial Position Details

Ajanta Pharma provided detailed financial information as part of its regulatory disclosure:

Parameter	Details
Outstanding Borrowings (March 31, 2026)	Nil
Credit Rating	CARE A1+
Rating Agency	CARE Ratings Limited
Designated Stock Exchange for Fines	NSE

SEBI Framework Context

The SEBI circular establishes specific criteria for identifying Large Corporate entities and mandates certain borrowing requirements through debt securities. Under this framework, entities classified as Large Corporates must meet mandatory borrowing thresholds through debt markets. The regulation also stipulates that beginning from FY 2022, any shortfall in mandatory borrowing through debt securities would attract a fine of 0.20% of the shortfall amount, levied by stock exchanges at the end of each two-year block period.

Corporate Governance Compliance

By confirming its non-applicability status, Ajanta Pharma demonstrates proactive regulatory compliance and transparent corporate governance practices. The company's nil outstanding borrowings position and strong credit rating reflect its financial stability and prudent capital management approach.

The formal disclosure ensures that investors and regulatory authorities have clear visibility into the company's status under the SEBI debt securities framework, maintaining transparency in corporate communications and regulatory adherence.